Ascentage Pharma Group International (HKG: 6855)
Hong Kong
· Delayed Price · Currency is HKD 42.95
-1.20 (-2.72%)
Dec 20, 2024, 4:08 PM HKT
Ascentage Pharma Group International Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2016 |
| Revenue | 903.03 | 221.98 | 209.71 | 27.91 | 12.45 | 14.51 | Upgrade
|
| Revenue Growth (YoY) | 251.85% | 5.85% | 651.38% | 124.18% | -14.21% | 113.21% | Upgrade
|
| Cost of Revenue | 27.45 | 30.54 | 22 | 3.33 | 1.97 | 2.1 | Upgrade
|
| Gross Profit | 875.58 | 191.44 | 187.71 | 24.58 | 10.48 | 12.42 | Upgrade
|
| Selling, General & Admin | 378.43 | 376.46 | 328.02 | 191.26 | 130.34 | 161.64 | Upgrade
|
| Research & Development | 841.24 | 706.97 | 743.1 | 766.49 | 564.57 | 463.88 | Upgrade
|
| Operating Expenses | 1,220 | 1,083 | 1,071 | 957.75 | 694.91 | 625.53 | Upgrade
|
| Operating Income | -344.09 | -891.99 | -883.41 | -933.17 | -684.43 | -613.11 | Upgrade
|
| Interest Expense | -77.41 | -96.06 | -52.79 | -16.73 | -6.26 | -4.27 | Upgrade
|
| Interest & Investment Income | 35.73 | 32.41 | 9.73 | 7.11 | 5.22 | 12.91 | Upgrade
|
| Earnings From Equity Investments | -0.37 | 1.08 | -0.28 | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 1.72 | 1.62 | -2.64 | 9.91 | 17.09 | 0.43 | Upgrade
|
| Other Non Operating Income (Expenses) | 15.1 | 20.78 | 49.91 | 139.47 | 19 | -806.37 | Upgrade
|
| EBT Excluding Unusual Items | -369.33 | -932.17 | -879.48 | -793.41 | -649.38 | -1,410 | Upgrade
|
| Gain (Loss) on Sale of Investments | -1.04 | -0.7 | -9.77 | -20.89 | -3.75 | -30.69 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0 | 0 | 2.07 | -0.03 | - | - | Upgrade
|
| Other Unusual Items | - | - | - | -17.92 | -22.33 | -41.21 | Upgrade
|
| Pretax Income | -370.36 | -932.86 | -887.17 | -832.25 | -675.45 | -1,482 | Upgrade
|
| Income Tax Expense | -9.83 | -7.15 | -4.25 | -49.83 | 2.16 | -1.6 | Upgrade
|
| Earnings From Continuing Operations | -360.54 | -925.71 | -882.92 | -782.42 | -677.61 | -1,481 | Upgrade
|
| Minority Interest in Earnings | 0.25 | 0.08 | - | - | - | - | Upgrade
|
| Net Income | -360.29 | -925.64 | -882.92 | -782.42 | -677.61 | -1,481 | Upgrade
|
| Net Income to Common | -360.29 | -925.64 | -882.92 | -782.42 | -677.61 | -1,481 | Upgrade
|
| Shares Outstanding (Basic) | 291 | 282 | 264 | 255 | 216 | 117 | Upgrade
|
| Shares Outstanding (Diluted) | 291 | 282 | 264 | 255 | 216 | 117 | Upgrade
|
| Shares Change (YoY) | 8.10% | 7.07% | 3.56% | 17.93% | 84.97% | 40.52% | Upgrade
|
| EPS (Basic) | -1.24 | -3.28 | -3.35 | -3.07 | -3.14 | -12.69 | Upgrade
|
| EPS (Diluted) | -1.24 | -3.28 | -3.35 | -3.07 | -3.14 | -12.69 | Upgrade
|
| Free Cash Flow | -740.66 | -772.19 | -857.2 | -1,040 | -859.88 | -537.76 | Upgrade
|
| Free Cash Flow Per Share | -2.55 | -2.74 | -3.25 | -4.08 | -3.98 | -4.61 | Upgrade
|
| Gross Margin | 96.96% | 86.24% | 89.51% | 88.08% | 84.21% | 85.56% | Upgrade
|
| Operating Margin | -38.10% | -401.83% | -421.25% | -3343.50% | -5497.42% | -4224.55% | Upgrade
|
| Profit Margin | -39.90% | -416.98% | -421.02% | -2803.38% | -5442.62% | -10202.67% | Upgrade
|
| Free Cash Flow Margin | -82.02% | -347.86% | -408.75% | -3726.60% | -6906.64% | -3705.37% | Upgrade
|
| EBITDA | -263.09 | -812.82 | -835.99 | -915.99 | -667.46 | -596.26 | Upgrade
|
| D&A For EBITDA | 81 | 79.17 | 47.42 | 17.18 | 16.97 | 16.85 | Upgrade
|
| EBIT | -344.09 | -891.99 | -883.41 | -933.17 | -684.43 | -613.11 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.